EP4164607A4 - MÉTHODES ET COMPOSITIONS POUR PRÉVENIR ET TRAITER LA MYOPIE À L'AIDE DE BROMHYDRATE DE FÉNOTÉROL, UN AGONISTE DU RÉCEPTEUR ß2-ADRÉNERGIQUE, ET DE SES DÉRIVÉS - Google Patents

MÉTHODES ET COMPOSITIONS POUR PRÉVENIR ET TRAITER LA MYOPIE À L'AIDE DE BROMHYDRATE DE FÉNOTÉROL, UN AGONISTE DU RÉCEPTEUR ß2-ADRÉNERGIQUE, ET DE SES DÉRIVÉS

Info

Publication number
EP4164607A4
EP4164607A4 EP21822599.3A EP21822599A EP4164607A4 EP 4164607 A4 EP4164607 A4 EP 4164607A4 EP 21822599 A EP21822599 A EP 21822599A EP 4164607 A4 EP4164607 A4 EP 4164607A4
Authority
EP
European Patent Office
Prior art keywords
derivatives
compositions
preventing
methods
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21822599.3A
Other languages
German (de)
English (en)
Other versions
EP4164607A1 (fr
Inventor
Andrei V Tkatchenko
Tatiana V Tkatchenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP4164607A1 publication Critical patent/EP4164607A1/fr
Publication of EP4164607A4 publication Critical patent/EP4164607A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP21822599.3A 2020-06-11 2021-06-09 MÉTHODES ET COMPOSITIONS POUR PRÉVENIR ET TRAITER LA MYOPIE À L'AIDE DE BROMHYDRATE DE FÉNOTÉROL, UN AGONISTE DU RÉCEPTEUR ß2-ADRÉNERGIQUE, ET DE SES DÉRIVÉS Pending EP4164607A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063037891P 2020-06-11 2020-06-11
PCT/US2021/036614 WO2021252626A1 (fr) 2020-06-11 2021-06-09 MÉTHODES ET COMPOSITIONS POUR PRÉVENIR ET TRAITER LA MYOPIE À L'AIDE DE BROMHYDRATE DE FÉNOTÉROL, UN AGONISTE DU RÉCEPTEUR β2-ADRÉNERGIQUE, ET DE SES DÉRIVÉS

Publications (2)

Publication Number Publication Date
EP4164607A1 EP4164607A1 (fr) 2023-04-19
EP4164607A4 true EP4164607A4 (fr) 2024-07-10

Family

ID=78846491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21822599.3A Pending EP4164607A4 (fr) 2020-06-11 2021-06-09 MÉTHODES ET COMPOSITIONS POUR PRÉVENIR ET TRAITER LA MYOPIE À L'AIDE DE BROMHYDRATE DE FÉNOTÉROL, UN AGONISTE DU RÉCEPTEUR ß2-ADRÉNERGIQUE, ET DE SES DÉRIVÉS

Country Status (7)

Country Link
EP (1) EP4164607A4 (fr)
JP (1) JP2023530679A (fr)
KR (1) KR20230051152A (fr)
CN (1) CN116194094A (fr)
CA (1) CA3182397A1 (fr)
IL (1) IL298974A (fr)
WO (1) WO2021252626A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020251926A1 (fr) * 2019-06-10 2020-12-17 Jenivision Inc. Méthodes et compositions de traitement de troubles de la vue

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569903B2 (en) * 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
WO2010125416A1 (fr) * 2009-04-27 2010-11-04 Raouf Rekik Administration de médicaments dans le segment antérieur et le segment postérieur de l'oeil
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
WO2015138700A1 (fr) * 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Utilisation de zwitterions anticholinergiques sélectionnés
WO2016172712A2 (fr) * 2015-04-23 2016-10-27 Sydnexis, Inc. Composition ophtalmique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020251926A1 (fr) * 2019-06-10 2020-12-17 Jenivision Inc. Méthodes et compositions de traitement de troubles de la vue

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021252626A1 *
TATIANA V. TKATCHENKO: "Analysis of genetic networks regulating refractive eye development in collaborative cross progenitor strain mice reveals new genes and pathways underlying human myopia", BMC MEDICAL GENOMICS, vol. 12, no. 1, 30 July 2019 (2019-07-30), London UK, XP093163579, ISSN: 1755-8794, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12920-019-0560-1/fulltext.html> DOI: 10.1186/s12920-019-0560-1 *
TATIANA V. TKATCHENKO: "Gene expression in response to optical defocus of opposite signs reveals bidirectional mechanism of visually guided eye growth", PLOS BIOLOGY, vol. 16, no. 10, 9 October 2018 (2018-10-09), US, pages e2006021, XP093163623, ISSN: 1545-7885, DOI: 10.1371/journal.pbio.2006021 *
TATIANA V. TKATCHENKO: "Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way", TRENDS IN PHARMACOLOGICAL SCIENCES., vol. 40, no. 11, 1 November 2019 (2019-11-01), GB, pages 833 - 852, XP093163629, ISSN: 0165-6147, DOI: 10.1016/j.tips.2019.09.009 *

Also Published As

Publication number Publication date
KR20230051152A (ko) 2023-04-17
IL298974A (en) 2023-02-01
CN116194094A (zh) 2023-05-30
CA3182397A1 (fr) 2021-12-16
JP2023530679A (ja) 2023-07-19
WO2021252626A1 (fr) 2021-12-16
EP4164607A1 (fr) 2023-04-19

Similar Documents

Publication Publication Date Title
EP3978490A4 (fr) Régulateur dérivé hétérocyclique contenant de l&#39;azote, son procédé de préparation et son application
IL286733A (en) Compound, pharmaceutical composition and method for modulating dux4 expression
PH12017501060B1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
IL283693A (en) Compounds and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
EP4194441A4 (fr) Dérivé de nitroxoline, son procédé de préparation et son utilisation
HK1164863A1 (en) Cyclopropyl amide derivatives targeting the histamine h3 receptor
IL276244A (en) A pharmaceutical preparation for the eyes, a method for its preparation and its application
EP4378935A4 (fr) Agent de régulation de sting benzo [b] sélénophène, son procédé de préparation et son utilisation
EP4164607A4 (fr) MÉTHODES ET COMPOSITIONS POUR PRÉVENIR ET TRAITER LA MYOPIE À L&#39;AIDE DE BROMHYDRATE DE FÉNOTÉROL, UN AGONISTE DU RÉCEPTEUR ß2-ADRÉNERGIQUE, ET DE SES DÉRIVÉS
EP3998091A4 (fr) Matériau d&#39;ingénierie tissulaire pour la réparation de lésions nerveuses, procédé de préparation associé et application correspondante
EP3760215A4 (fr) Composition destinée à prévenir, atténuer ou traiter la cachexie et la fonte musculaire
GB2603330B (en) Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
EP4119555A4 (fr) Agoniste du récepteur glp-1, composition pharmaceutique le comprenant et son procédé de préparation
EP3603647A4 (fr) Composition pharmaceutique pour la prévention et le traitement du glaucome, contenant un dérivé d&#39;adénosine
EP4157453A4 (fr) Méthodes et compositions pour la prévention et le traitement de la myopie avec de la lévocabastine, un antagoniste sélectif du récepteur h1 de l&#39;histamine et des dérivés de celui-ci
EP4005578A4 (fr) Composition pour prévenir, soulager ou traiter une lésion hépatique
IL283748A (en) Preparations and methods for improving body weight and lean muscle mass using antagonists against the leptin receptor, gdf8 and activin a
EP4164640A4 (fr) Méthodes et compositions pour prévenir et traiter la myopie avec de la berbérine, un alcaloïde de berbéridacée, et des dérivés de celle-ci
EP3937607A4 (fr) Dispositif de calcul de quantité de correction, machine de montage de composant et procédé de calcul de quantité de correction
EP4240330A4 (fr) Composition comprenant des composés hétérocycliques, son procédé de préparation et son application
EP4349828A4 (fr) Composé hétérocyclique contenant de l&#39;azote, son procédé de préparation et son application
EP4223757A4 (fr) Agoniste de petites molécules de fxr, son procédé de préparation et son utilisation
EP3986856A4 (fr) Compositions et méthodes de traitement du syndrome de l&#39;hyperémésie cannabinoïde avec un antagoniste du récepteur des cannabinoïdes
EP4166065A4 (fr) Dispositif ophtalmique, procédé de commande de dispositif ophtalmique et programme
EP4324593A4 (fr) Dispositif de porte pour machine-outil et machine-outil

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230606

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009000000

Ipc: A61K0031137000

A4 Supplementary search report drawn up and despatched

Effective date: 20240607

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/10 20060101ALI20240603BHEP

Ipc: A61K 9/00 20060101ALI20240603BHEP

Ipc: A61K 31/137 20060101AFI20240603BHEP